See more : Gubra A/S (GUBRA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Colfax Corporation (CFXA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Colfax Corporation, a leading company in the Industrial – Machinery industry within the Industrials sector.
- Visio Nerf (MLVIS.PA) Income Statement Analysis – Financial Results
- Lincoln Gold Mining Inc. (LNCLF) Income Statement Analysis – Financial Results
- KUKA Aktiengesellschaft (KUKAF) Income Statement Analysis – Financial Results
- Golkonda Aluminium Extrusions Limited (GOLKONDA.BO) Income Statement Analysis – Financial Results
- Saudi Basic Industries Corporation (2010.SR) Income Statement Analysis – Financial Results
Colfax Corporation (CFXA)
About Colfax Corporation
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is based in Wilmington, Delaware.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.71B | 1.56B | 3.85B | 3.07B | 3.33B | 3.67B | 3.30B | 3.65B | 3.97B | 4.62B | 4.21B | 3.91B | 693.39M | 541.99M | 525.02M | 604.85M | 506.31M | 393.60M | 345.48M | 309.65M |
Cost of Revenue | 716.42M | 693.72M | 2.24B | 1.78B | 1.93B | 2.53B | 2.27B | 2.50B | 2.72B | 3.15B | 2.90B | 2.76B | 453.29M | 350.58M | 339.24M | 387.67M | 330.71M | 256.81M | 222.35M | 197.91M |
Gross Profit | 990.78M | 869.38M | 1.61B | 1.29B | 1.40B | 1.13B | 1.03B | 1.15B | 1.25B | 1.48B | 1.31B | 1.15B | 240.10M | 191.41M | 185.79M | 217.19M | 175.59M | 136.80M | 123.13M | 111.75M |
Gross Profit Ratio | 58.04% | 55.62% | 41.87% | 41.95% | 42.11% | 30.89% | 31.19% | 31.41% | 31.55% | 31.98% | 31.05% | 29.44% | 34.63% | 35.32% | 35.39% | 35.91% | 34.68% | 34.76% | 35.64% | 36.09% |
Research & Development | 75.33M | 60.83M | 49.09M | 68.60M | 61.80M | 34.20M | 42.90M | 39.30M | 41.50M | 43.00M | 27.40M | 19.40M | 5.71M | 6.21M | 5.93M | 5.86M | 4.16M | 3.34M | 2.86M | 3.18M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 843.99M | 879.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00M | 15.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 830.31M | 772.91M | 1.33B | 1.09B | 1.13B | 818.21M | 732.34M | 825.24M | 905.95M | 1.01B | 860.99M | 895.45M | 144.82M | 119.43M | 113.67M | 125.23M | 98.50M | 113.92M | 92.71M | 77.43M |
Other Expenses | 150.85M | 126.30M | 11.21M | 0.00 | -33.62M | 39.00K | -46.93M | -8.23M | -21.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -50.35M | 0.00 | 0.00 | 29.41M |
Operating Expenses | 1.06B | 960.04M | 1.33B | 1.09B | 1.13B | 818.21M | 732.34M | 825.24M | 905.95M | 1.01B | 860.99M | 895.45M | 150.52M | 125.63M | 117.41M | 200.50M | 52.32M | 117.26M | 95.56M | 110.02M |
Cost & Expenses | 1.77B | 1.65B | 3.57B | 2.87B | 3.06B | 3.35B | 3.00B | 3.33B | 3.62B | 4.16B | 3.76B | 3.66B | 603.82M | 476.21M | 456.65M | 588.17M | 383.03M | 374.06M | 317.91M | 307.93M |
Interest Income | 0.00 | 200.00K | 200.00K | 3.20M | 3.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 19.75M | 24.05M | 72.59M | 104.26M | 119.50M | 44.05M | 41.14M | 30.02M | 47.74M | 51.31M | 103.60M | 91.57M | 5.92M | 6.68M | 7.21M | 11.82M | 0.00 | 0.00 | 0.00 | 6.92M |
Depreciation & Amortization | 217.10M | 202.90M | 187.00M | 246.23M | 236.03M | 141.88M | 123.42M | 109.87M | 154.54M | 174.72M | 119.26M | 200.40M | 22.60M | 16.13M | 15.07M | 14.79M | 16.88M | 13.14M | 12.91M | 0.00 |
EBITDA | 169.92M | 225.78M | 95.03M | 180.05M | 409.22M | 330.29M | 160.41M | 349.27M | 430.59M | 409.55M | 525.65M | 140.01M | 25.91M | 34.37M | 54.70M | 16.69M | 140.16M | 32.68M | 38.99M | 1.73M |
EBITDA Ratio | 9.95% | 8.39% | 14.49% | 14.55% | 14.16% | 12.45% | 11.66% | 12.49% | 12.61% | 13.89% | 13.42% | 6.56% | 12.92% | 15.11% | 15.89% | 5.20% | 17.74% | 8.30% | 11.72% | 0.56% |
Operating Income | -65.71M | -88.57M | 256.64M | 162.29M | 203.61M | 236.94M | 29.15M | 238.02M | 284.65M | 409.55M | 406.39M | 140.01M | 25.91M | 34.37M | 38.46M | 16.69M | 123.28M | 19.54M | 27.56M | 1.73M |
Operating Income Ratio | -3.85% | -5.67% | 6.66% | 5.29% | 6.12% | 6.46% | 0.88% | 6.53% | 7.18% | 8.86% | 9.66% | 3.58% | 3.74% | 6.34% | 7.33% | 2.76% | 24.35% | 4.97% | 7.98% | 0.56% |
Total Other Income/Expenses | -1.42M | 36.12M | -58.98M | -104.26M | -153.12M | -59.17M | -147.58M | -30.32M | -28.72M | -51.31M | -103.60M | -91.57M | -5.92M | -6.68M | -6.04M | -11.82M | -19.25M | -14.19M | -9.03M | -6.92M |
Income Before Tax | -67.13M | -2.07M | 165.39M | 58.03M | 50.49M | 182.80M | -11.99M | 208.00M | 236.90M | 358.25M | 302.80M | 48.44M | 19.99M | 27.69M | 31.25M | 4.87M | 104.03M | 5.36M | 18.54M | -5.19M |
Income Before Tax Ratio | -3.93% | -0.13% | 4.29% | 1.89% | 1.52% | 4.99% | -0.36% | 5.70% | 5.97% | 7.75% | 7.20% | 1.24% | 2.88% | 5.11% | 5.95% | 0.80% | 20.55% | 1.36% | 5.37% | -1.68% |
Income Tax Expense | -13.29M | 36.12M | 66.70M | -6.05M | 31.63M | -21.00K | 42.55M | 62.81M | 49.72M | -62.03M | 93.65M | 90.70M | 15.43M | 11.47M | 9.53M | 5.44M | 39.15M | 3.87M | 6.91M | -6.01M |
Net Income | -33.26M | -38.19M | 98.69M | 64.08M | 18.86M | 140.20M | 151.09M | 128.11M | 167.74M | 392.10M | 178.63M | -64.40M | 4.56M | 16.22M | 21.72M | -571.00K | 64.88M | 94.00K | 12.25M | 57.31M |
Net Income Ratio | -1.95% | -2.44% | 2.56% | 2.09% | 0.57% | 3.82% | 4.58% | 3.51% | 4.23% | 8.48% | 4.25% | -1.65% | 0.66% | 2.99% | 4.14% | -0.09% | 12.81% | 0.02% | 3.54% | 18.51% |
EPS | -0.89 | -0.71 | 1.93 | 1.41 | 0.42 | 3.50 | 3.69 | 3.12 | 4.05 | 9.18 | 4.68 | -2.13 | 0.30 | 1.11 | 1.50 | -0.05 | 5.37 | 0.03 | -0.18 | -1.86 |
EPS Diluted | -0.90 | -0.71 | 1.93 | 1.38 | 0.41 | 3.48 | 3.66 | 3.12 | 4.02 | 9.06 | 4.62 | -2.13 | 0.30 | 1.11 | 1.50 | -0.05 | 5.37 | 0.03 | -0.18 | -1.86 |
Weighted Avg Shares Out | 54.53M | 54.07M | 51.14M | 45.59M | 45.24M | 40.10M | 40.95M | 41.06M | 41.42M | 40.33M | 33.44M | 30.20M | 14.76M | 14.61M | 14.48M | 11.20M | 7.30M | 7.30M | 7.30M | 7.30M |
Weighted Avg Shares Out (Dil) | 54.49M | 54.07M | 51.14M | 46.30M | 45.56M | 40.29M | 41.33M | 41.07M | 41.62M | 41.34M | 33.81M | 30.20M | 14.76M | 14.61M | 14.48M | 11.20M | 7.30M | 7.30M | 7.30M | 7.30M |
Forget The Covid Apocalypse, Focus On Stocks That Closed Green After Friday's Monster Sell Off
Stanley Black & Decker (NASDAQ:CFXA) Stock Price Up 8.6%
TheStreet Downgrades Stanley Black & Decker (NASDAQ:CFXA) to D+
CFXA Stock Price, Forecast & News (Stanley Black & Decker)
Source: https://incomestatements.info
Category: Stock Reports